Search

Search Constraints

You searched for: Author/Creator Cardone, C

Search Results

1. 18PCombination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four consensus molecular subtypes. (23rd October 2018)

2. 25PFunctional inhibition of TGF-β in colorectal cancer cells and its interaction with AXL receptor. (23rd October 2018)

3. 2OReceptor tyrosine kinase dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated colorectal cancer cell lines. (23rd October 2018)

4. 598PMacrophage migration inhibitory factor overexpression is a mechanism of acquired resistance to anti-EGFR inhibitor cetuximab in human colorectal cancer cell line. (23rd October 2018)

5. 66PDual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer. (1st October 2019)

6. 96PAXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts). (23rd October 2018)

8. P-326Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience. (2nd July 2019)

9. P-330Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data. (2nd July 2019)

10. PD-019Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS. (2nd July 2019)